Date: 2011-08-10
Type of information: Licensing agreement
Compound: GlymaxX® Antibody Glyco-Engineering technology
Company: Boehringer Ingelheim (Germany) Probiogen (Germany)
Therapeutic area:
Type agreement: licensing
Action mechanism: The GlymaxX® technology is used for production of afucosylated proteins and can also be applied to already existing antibody producer cell lines without altering their productivity. The technology can easily be integrated into Boehringer Ingelheim’s high expression CHO-based BI-HEX® system.
Disease:
Details: Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.
Financial terms:
Latest news:
